TY - JOUR
T1 - Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy
T2 - An EMAS clinical guide
AU - Hirschberg, Angelica Lindén
AU - Bitzer, Johannes
AU - Cano, Antonio
AU - Ceausu, Iuliana
AU - Chedraui, Peter
AU - Durmusoglu, Fatih
AU - Erkkola, Risto
AU - Goulis, Dimitrios G.
AU - Kiesel, Ludwig
AU - Lopes, Patrice
AU - Pines, Amos
AU - van Trotsenburg, Mick
AU - Lambrinoudaki, Irene
AU - Rees, Margaret
N1 - Publisher Copyright:
© 2021
PY - 2021/6
Y1 - 2021/6
N2 - Introduction: Vulvovaginal atrophy (VVA) is a chronic condition caused by estrogen deficiency. It affects around 50% of postmenopausal women, reducing their general and sexual quality of life as well as the quality of their personal relationships. Aim: The aim of this clinical guide is to set out an individualized approach to the management of VVA with topical estrogens and non-hormonal preparations. Materials and methods: Literature review and consensus of expert opinion. Summary recommendations: An individualized approach is required for the management of VVA. Topical low-dose estrogens are effective and also alleviate urinary incontinence and prevent recurrent urinary tract infections. Women should not be denied long-term use of topical estrogens as long as they feel that this treatment is of benefit to them, because the safety data are reassuring. Non-hormonal preparations (lubricants and moisturizers) should be the first-line treatment for VVA in women taking adjuvant endocrine therapies for cancers considered to be hormone-dependent. They can be used over the long term.
AB - Introduction: Vulvovaginal atrophy (VVA) is a chronic condition caused by estrogen deficiency. It affects around 50% of postmenopausal women, reducing their general and sexual quality of life as well as the quality of their personal relationships. Aim: The aim of this clinical guide is to set out an individualized approach to the management of VVA with topical estrogens and non-hormonal preparations. Materials and methods: Literature review and consensus of expert opinion. Summary recommendations: An individualized approach is required for the management of VVA. Topical low-dose estrogens are effective and also alleviate urinary incontinence and prevent recurrent urinary tract infections. Women should not be denied long-term use of topical estrogens as long as they feel that this treatment is of benefit to them, because the safety data are reassuring. Non-hormonal preparations (lubricants and moisturizers) should be the first-line treatment for VVA in women taking adjuvant endocrine therapies for cancers considered to be hormone-dependent. They can be used over the long term.
UR - http://www.scopus.com/inward/record.url?scp=85106279881&partnerID=8YFLogxK
U2 - 10.1016/j.maturitas.2021.04.005
DO - 10.1016/j.maturitas.2021.04.005
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 33896654
AN - SCOPUS:85106279881
SN - 0378-5122
VL - 148
SP - 55
EP - 61
JO - Maturitas
JF - Maturitas
ER -
